Anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis: A case report
A 56-year-old male presented to the clinic for follow-up of severe, longstanding hidradenitis suppurativa. On physical examination, there was a linear Blaschkoid distribution of erythematous scaly papules extending from the left upper arm toward the scapular mid-back region. A clinical diagnosis of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X241304954 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | A 56-year-old male presented to the clinic for follow-up of severe, longstanding hidradenitis suppurativa. On physical examination, there was a linear Blaschkoid distribution of erythematous scaly papules extending from the left upper arm toward the scapular mid-back region. A clinical diagnosis of linear psoriasis was made, and the patient’s dosage interval of infliximab was decreased to every 6 weeks. The patient was offered Betamethasone diproprionate/calcipotriol (Enstilar) topical foam to use daily which demonstrated efficacy in clearing 90% of the affected areas. This case illustrates the potential for Betamethasone diproprionate/calcipotriol (Enstilar) topical foam use as a treatment approach for anti-tumor necrosis factor-alpha inhibitor-induced linear psoriasis. At present there is no consensus on linear psoriasis pathogenesis or best treatment approach, therefore, more research is needed to understand its pathogenesis and establish management guidelines. |
|---|---|
| ISSN: | 2050-313X |